Skip to main content
. 2008 Apr 8;57(12):1817–1825. doi: 10.1007/s00262-008-0509-2

Fig. 1.

Fig. 1

Diagram of all patients in trial (n = 186). Overall, enrollment withdrawals and recurrences are per vaccinated and control groups. Disease-free breast cancer patients were HLA typed; excluding withdrawals HLA-A2/A3 patients were followed prospectively as controls (n = 81), and HLA-A2+/A3+ patients were vaccinated (n = 96). Recurrence rate in control and vaccinated groups were 14.8 and 8.3%, respectively (P = 0.17)